Cargando…
Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle
Premenstrual dysphoric disorder (PMDD) is a severe mood disorder with core symptoms (affective lability, irritability, depressed mood, anxiety) and increased sensitivity to stress occurring in the luteal phase of the menstrual cycle. PMDD can be conceptualized as a disorder of suboptimal sensitivity...
Autores principales: | Hantsoo, Liisa, Epperson, C. Neill |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231988/ https://www.ncbi.nlm.nih.gov/pubmed/32435664 http://dx.doi.org/10.1016/j.ynstr.2020.100213 |
Ejemplares similares
-
Realising the therapeutic potential of neuroactive steroid modulators of the GABA(A) receptor
por: Belelli, Delia, et al.
Publicado: (2019) -
Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
por: Meltzer-Brody, Samantha, et al.
Publicado: (2020) -
The role of allopregnanolone in depressive-like behaviors: Focus on neurotrophic proteins
por: Almeida, Felipe Borges, et al.
Publicado: (2020) -
Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective
por: Paul, Steven M, et al.
Publicado: (2020) -
Allopregnanolone-based treatments for postpartum depression: Why/how do they work?
por: Walton, Najah, et al.
Publicado: (2019)